Pharmiweb.com

New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models Findings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers Data to be presented today as a poster...

Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to host investor webcast showcasing momentum across solid tumor pipeline SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd.

SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced the expansion of its Acute Kidney Injury (AKI) Advisory Board, with the addition of two new members, Dr. Peter Pickkers and Dr. Lui Forni, ahead of its upcoming Phase 2/3 clinical trial.

Pesticides. Mycotoxins. Fraudulent Lab Reports. Forged Certificates of Analysis. This Is the State-Licensed Cannabis and Hemp Supply Chain the Courts and DEA Just Handed a Federal Registration Pathway - While the FDA Commissioner Looked Away and Judge McFadden Said Nobody Has Standing to Complain. WASHINGTON, D.C. / ACCESS Newswire / June 1, 2026 / Let's start with what medicine actually is. Pesticides. Mycotoxins. Fraudulent Lab Reports. Now Covered by Medicare.

Company highlights streamlined body-map tracking and image management features designed to support long-term skin monitoring workflows MESA, AZ / ACCESS Newswire / June 1, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE), ("MDCE" or the "Company") a technology company focused on AI-powered imaging and wellness applications, today provided additional details regarding the user experience and interface design objectives currently being incorporated into the MDCE Melanoma Scan Beta platform.

Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to host investor webcast showcasing momentum across solid tumor pipeline SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd.

First-ever immunotherapy combination approved in Europe for adult and adolescent patients, ages 12 and older, with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL) PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #HodgkinLymphoma--Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and adolescent patients 12 years of age and...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Lysoway Therapeutics, a biopharmaceutical company developing small-molecule modulators of lysosomal ion channels, today announced that it has been awarded an additional research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support development of its TMEM175 agonist program for Parkinson’s disease.

Synexis®, LLC, the leader in touchless, continuous pathogen control technology, today announced a strategic collaboration with Midwest Veterinary Supply to bring Synexis DHP® technology to animal health professionals nationwide.

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet.